CARLSBAD, CA--(Marketwire - October 25, 2012) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company focused on therapeutic and research products, today announced that its subsidiary, Lifeline Cell Technology (LCT), will begin selling products through Fisher Scientific, Inc.'s ("Fisher Scientific") online catalogue as an Encompass Preferred Supplier.
Typically large pharmaceutical companies buy research supplies and products using preferred supplier agreements. Fisher Scientific is the world's largest such supplier to the life science industry with over 350,000 customers and $12 billion in annual sales. Their third party e-catalog sales have grown from $26 million in 2006 to $424 million in 2011 and represent a promising new sales channel for Lifeline Cell Technology's cell and media products.
Dr. Simon Craw, ISCO's Executive Vice President of Business Development, explained, "This is a tremendous opportunity and a testament to the high quality of Life Cell Technology's products. By working with Fisher Scientific, LCT will be able to reach many more customers that we would otherwise not be able to reach. One of the biggest challenges we faced was the ability to sell into pharmaceutical companies that have preferred supplier agreements. Our inclusion in the Fisher e-catalogs and Encompass Preferred Suppliers list, not only validates LCT's focus on delivering high quality products but also means these products can now be purchased much more easily by scientists working at the some of the world's largest life science companies."
About Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific is a global leader in serving science. Fisher Scientific, one of the corporation's premier brands, provides a complete portfolio of laboratory equipment, chemicals, supplies and services for research, safety, healthcare and science education. For more information, visit www.thermofisher.com.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell